Trial 1B-23-3


A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Daphne Stewart, M.D.
Other Trial Staff:  Marissa Aldana, Coordinator, Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Apoorva Vishwanath, D.M., Othesia Glasgow, D.M., Maria Kaufman, Coordinator, Kimberly Arieli, Coordinator, Alejandro Baltazar, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.